More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
Journal of Clinical Oncology · 01.03.2023 · 41 (7) · 1383-1392
DOI: 10.1200/jco.22.01226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2023. Verfasst von Tomas Jelinek und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Multiple Myeloma, Leukemia, Plasma Cell, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
- Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
- Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
- Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic.
- Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czech Republic.
ORCID-Profile: Tomas Jelinek, Renata Bezdekova, David Zihala, Tereza Sevcikova, Anjana Anilkumar Sithara, Ondrej Venglar, Veronika Kapustova, Tereza Popkova, Zuzana Chyra, Matous Hrdinka, Michal Simicek, Juan-Jose Garcés, Noemi Puig, Maria-Teresa Cedena, Jorge J Castillo, Jakub Radocha, Maria Victoria Mateos, Jesús F San-Miguel, Bruno Paiva, Ludek Pour, Lucie Rihova, Roman Hajek
Förderung
- Cancer Research UK
Zitieren
APA
Jelinek, T., Bezdekova, R., Zihala, D., Sevcikova, T., Anilkumar Sithara, A., Pospisilova, L., Sevcikova, S., Polackova, P., Stork, M., Knechtova, Z., Venglar, O., Kapustova, V., Popkova, T., Muronova, L., Chyra, Z., Hrdinka, M., Simicek, M., Garcés, J. J., Puig, N., …, & Hajek, R. (2023). More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma. Journal of Clinical Oncology, 41(7), 1383-1392. https://doi.org/10.1200/jco.22.01226
Vancouver
Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma. Journal of Clinical Oncology. 2023;41(7):1383-1392. doi:10.1200/jco.22.01226
BibTeX
@article{Jelinek2023,
author = {Jelinek, Tomas and Bezdekova, Renata and Zihala, David and Sevcikova, Tereza and Anilkumar Sithara, Anjana and Pospisilova, Lenka and Sevcikova, Sabina and Polackova, Petra and Stork, Martin and Knechtova, Zdenka and Venglar, Ondrej and Kapustova, Veronika and Popkova, Tereza and Muronova, Ludmila and Chyra, Zuzana and Hrdinka, Matous and Simicek, Michal and Garcés, Juan-Jose and Puig, Noemi and Cedena, Maria-Teresa and Jurczyszyn, Artur and Castillo, Jorge J and Penka, Miroslav and Radocha, Jakub and Mateos, Maria Victoria and San-Miguel, Jesús F and Paiva, Bruno and Pour, Ludek and Rihova, Lucie and Hajek, Roman},
title = {More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {7},
pages = {1383--1392},
doi = {10.1200/jco.22.01226}
}
EUVIMED